Skip to main content
. 2023 Apr 15;7(14):3666–3676. doi: 10.1182/bloodadvances.2022009493

Table 2.

OS, RFS, CIR, and TRM at 2 years from the time of MRD assessment based on the MRD status at each time point

Outcome Time point Posttransplant MRD
Positive result
2-y estimate (95% CI)
Negative result
2-y estimate (95% CI)
P value
CIR D 42 92.3 (35.8-99.4) 22.9 (16.4-30.1) < .001
Mo 3 50.0 (19.2-74.8) 20.5 (14.0-27.7) .011
Mo 6 83.3 (8.6-98.7) 17.4 (11.1-24.9) < .001
Mo 9 100 (., .) 14.6 (8.5-22.1) < .001
Mo 12 50.0 (0.0-96.0) 14.0 (8.0-21.6) .19
OS D 42 30.8 (9.5-55.4) 66.9 (58.5-74.0) < .001
Mo 3 58.3 (27.0-80.1) 74.0 (65.5-80.6) .30
Mo 6 50.0 (11.1-80.4) 80.6 (72.0-86.8) < .0001
Mo 9 33.3 (0.9-77.4) 87.8 (79.5-92.9) < .0001
Mo 12 50.0 (0.6-91.0) 94.7 (87.8-97.8) .18
RFS D 42 7.7 (0.5-29.2) 61.0 (52.6-68.5) < .001
Mo 3 50.0 (20.8-73.6) 67.3 (58.6-74.6) .13
Mo 6 16.7 (0.8-51.7) 75.4 (66.3-82.3) < .001
Mo 9 33.3 (0.9-77.4) 79.3 (69.7-86.2) < .001
Mo 12 50.0 (0.6-91.0) 83.7 (74.4-89.9) .31
TRM D 42 16.9 (11.2, 23.5) .31
Mo 3 11.4 (6.7-17.6) .38
Mo 6 8.0 (3.9-13.9) .58
Mo 9 4.9 (1.8-10.3)
Mo 12 2.1 (0.4-6.8)

TRM, transplant-related mortality; —, null.